As lawyers prepare for the first Valsartan bellwether trials later this year, plans are moving forward for a second wave of cases to go before juries if settlements can not be reached with all drug makers.
Chronic hypertension did not significantly increase the risk of severe health problems during pregnancy for women who did not develop preeclampsia.
Valsartan settlement fund will be used to disburse payouts that may be made by different generic drug makers, after versions of the hypertension drug were distributed with cancer-causing contaminants.
Selections have been made in case the parties fail to negotiate Valsartan cancer settlements following a first round of bellwether trials expected to begin in late 2025.
Women diagnosed with eclampsia during pregnancy have a five times greater risk of developing epilepsy later in life, researchers have found.
Although Tylenol is widely believed to be safe, side effects have been linked to concerns about liver damage, skin reactions and developmental problems among children.
Parties will meet with the MDL judge today, to discuss issues scheduling the remaining bellwether trials selected by the Court.
Researchers warn that it is "vital" to reduce PFAS exposure for expecting mothers, given long-term health risks for unborn children.
Researchers indicate that more studies are needed to determine how to safely use the hypertension drugs before surgery, especially among minorities.
First bellwether trial in the valsartan MDL will involve claims brought by an Alabama man diagnosed with liver cancer, which is the most commonly reported injury caused by the recalled blood pressure drug.
